OP0129 Effectiveness of COBRA-Slim with or without early access to a temporary 6-month course of etanercept in early RA: primary outcome of the 2-year, pragmatic, randomised CareRA2020 trial

Bertrand, Delphine;Joly, Johan;Neerinckx, Barbara;Durez, Patrick;Verschueren, Patrick;et.al.
(2023) EULAR 2023 European Congress of Rheumatology — Location: (Italy) Milano (31.May.2023)

Files

2023_EULAR_OP0129.pdf
  • Open Access
  • Adobe PDF
  • 3.01 MB
Download

Details

Authors
  • Bertrand, Delphine
    Author
  • Joly, Johan
    Author
  • Neerinckx, Barbara
    Author
  • Durez, PatrickUCLouvain
    Author
  • Boutsen, YvesUCLouvain
    Author
  • Verschueren, Patrick
    Author
Show more
Abstract
BACKGROUND: EULAR recommends methotrexate (MTX), combined with shortterm glucocorticoids as first-line treatment for early Rheumatoid Arthritis (RA). In the CareRA trial, the COBRA-Slim regimen (MTX 15 mg/w + step-down prednisone 30, 20, 12.5, 10, 7.5, 5 mg/d), including a treat to target (T2T) approach starting with addition of leflunomide and only at a later stage bDMARDs, provided the best balance between efficacy, safety and cost-effectiveness. The potential advantage of temporary bDMARD use earlier in the T2T setting needs further investigation. OBJECTIVES: To determine the long-term effectiveness of accelerated access to a temporary course of etanercept compared to addition of leflunomide in patients with early RA who insufficiently respond to initial COBRA-Slim induction therapy. […]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Bertrand, D., Joly, J., Neerinckx, B., Durez, P., Lenaerts, J., Joos, R., Thevissen, K., Zwaenepoel, T., Geusens, P., Méric De Bellefon, L., Taelman, V., Van Essche, E., Corluy, L., Malaise, M., Vanden Berghe, M., Devink, M., Ajeganova, S., Durnez, A., Boutsen, Y., et al. (2023). OP0129 Effectiveness of COBRA-Slim with or without early access to a temporary 6-month course of etanercept in early RA: primary outcome of the 2-year, pragmatic, randomised CareRA2020 trial. Annals of the Rheumatic Diseases, 82(Suppl 1), 85. https://doi.org/10.1136/annrheumdis-2023-eular.2534 (Original work published 2023)